Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
The purpose of the study is to investigate, in patients with moderate to severe chronic obstructive lung disease, whether intermittent antibiotic treatment leads to: * A slower rate of decline in forced expiratory volume in one second (FEV1); * A reduction in the frequency and severity of exacerbations; * Fewer hospital admissions for chronic obstructive pulmonary disease (COPD); * Lower mortality; * An improved quality of life as compared to a group of placebo treated patients.
Detailed description
Study Population: Patients with moderate to severe chronic obstructive lung disease. Trial Phase: IV Study Design: Prospective, randomised, double-blind, placebo- controlled clinical trial. Study Medicine: Azithromycin. Drug Administration: Oral. Drug Dose: 500 mg once daily for 3 days every month. Duration of Treatment: 3 years Number of Evaluable Patients: 200 per treatment arm Number of Included Patients: 400 per treatment arm, 800 patients in total.
Interventions
DRUGazithromycin
Sponsors
Odense University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients above 50 years of age, with a current admission for exacerbation of COLD or at least one admission within the previous two years. * Current or ex-smoker * Postbronchodilator FEV1 \< 60% in stable condition (\> 4 weeks after hospitalisation) * \< 300 ml bronchodilator reversibility in FEV1
Exclusion criteria
* Patients with end-stage COLD, who are not expected to survive for 3 years (typically bedridden patients being dyspnoeic in rest). * Patients with known other respiratory tract infection, e.g. tuberculosis or aspergillosis, in whom the intervention is known to be inefficient. * Patients with pulmonary malignancy * Patients with other pulmonary diseases than COLD. * Patients with immunodeficiency. However, COLD patients treated with steroids can be included. * Patients with known hereditary disposition to lung infections such as alfa-1-antitrypsin deficiency, cystic fibrosis or primary ciliary dyskinesia. * Patients receiving longterm antibiotic treatment ( e.g. recurrent cystitis). * Patients with known allergy or intolerance to azithromycin * Pregnant or breastfeeding women * Manifest heart, liver or renal insufficiency * Patients that, for reasons not stated above, are unlikely to be able to participate in a study period of 3 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in postbronchodilator FEV1 | — |
Secondary
| Measure | Time frame |
|---|---|
| inflammatory parameters | — |
| number of hospital admissions and number of hospital days | — |
| mortality | — |
| prevalence of macrolide resistance | — |
| use of medication | — |
| prevalence of respiratory pathogens | — |
| quality of life | — |
Countries
Denmark
Outcome results
None listed